文献速递肾癌与肾肿瘤

IMmotion150 患者报告结局:阿替利珠单抗单药或联合贝伐珠单抗对比舒尼替尼

Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
PubMed 文献 · BJU Int · 2020-04-24

IMmotion150 二期研究纳入既往未治疗的转移性肾细胞癌患者,随机接受阿替利珠单抗单药、阿替利珠单抗联合贝伐珠单抗或舒尼替尼治疗。患者报告结局显示,阿替利珠单抗单药或联合方案相比舒尼替尼延迟了核心症状、肾癌症状、症状干扰及疲劳的恶化时间,其中单药组改善更明显。

要点

  • 阿替利珠单抗单药或联合贝伐珠单抗较舒尼替尼延迟核心症状和肾癌症状恶化。
  • 阿替利珠单抗单药组症状恶化风险改善最明显:核心症状 HR 0.39。
  • 研究样本量小,患者报告结局结论需谨慎解读。

核心结论

  • 患者报告结局提示阿替利珠单抗单药或联合贝伐珠单抗较舒尼替尼维持日常功能更好,症状最轻见于阿替利珠单抗单药组。

研究设计与样本

  • 二期 IMmotion150 研究,既往未治疗的转移性肾细胞癌患者随机接受阿替利珠单抗 1200 mg 每 3 周(n=103)、阿替利珠单抗联合贝伐珠单抗 15 mg/kg 每 3 周(n=101)或舒尼替尼 50 mg 口服每日(服 4 周停 2 周;n=101)。
  • 使用 MD Anderson 症状量表(MDASI)和简明疲劳量表(BFI)在每 6 周周期的第 1 天和第 22 天评估。

主要发现

  • 阿替利珠单抗单药组对比舒尼替尼的症状恶化时间(TTD)风险比:核心症状 HR 0.39(95%CI 0.22-0.71),肾癌症状 HR 0.22(95%CI 0.12-0.41),症状干扰 HR 0.36(95%CI 0.22-0.58)。
  • 阿替利珠单抗单药或联合贝伐珠单抗较舒尼替尼延迟了核心症状、肾癌症状、症状干扰、疲劳及疲劳相关干扰的恶化时间。
  • 按访视评估的 MDASI 基线变化也显示阿替利珠单抗单药对比舒尼替尼有改善趋势。

临床怎么用

  • 对于既往未治疗的转移性肾细胞癌患者,阿替利珠单抗单药或联合贝伐珠单抗可能较舒尼替尼更好地维持日常功能并减轻症状负担。

局限性

  • 样本量小可能限制得出确定性结论的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate patient-reported outcome (PRO) data from the IMmotion150 study. The phase 2 IMmotion150 study showed improved progression-free survival with atezolizumab plus bevacizumab vs sunitinib in patients with programmed death-ligand 1 (PD-L1)+ tumours and suggested activity of atezolizumab monotherapy in previously untreated metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Patients with previously untreated mRCC were randomised to atezolizumab 1200 mg intravenously (i.v.) every 3 weeks (n = 103), the atezolizumab regimen plus bevacizumab 15 mg/kg i.v. every 3 weeks (n = 101), or sunitinib 50 mg orally daily (4 weeks on, 2 weeks off; n = 101). The MD Anderson Symptom Inventory (MDASI) and Brief Fatigue Inventory (BFI) were administered on days 1 and 22 of each 6-week cycle. Time to deterioration (TTD), change from baseline in MDASI core and RCC symptom severity, interference with daily life, and BFI fatigue severity and interference scores were reported for all comers. The TTD was the first ≥2-point score increase over baseline. Absolute effect size ≥0.2 suggested a clinically important difference with checkpoint inhibitor therapy vs sunitinib. RESULTS: Completion rates were >90% at baseline and ≥80% at most visits. Delayed TTD in core and RCC symptoms, symptom interference, fatigue, and fatigue-related interference was observed with atezolizumab (both alone and in combination) vs sunitinib. Improved TTD (hazard ratio [HR], 95% confidence interval [CI]) was more pronounced with atezolizumab monotherapy: core symptoms, 0.39 (0.22-0.71); RCC symptoms, 0.22 (0.12-0.41); and symptom interference, 0.36 (0.22-0.58). Change from baseline by visit, evaluated by the MDASI, also showed a trend favouring atezolizumab monotherapy vs sunitinib. Small sample sizes may have limited the ability to draw definitive conclusions. CONCLUSION: PROs suggested that atezolizumab alone or with bevacizumab maintained daily function compared with sunitinib. Notably, symptoms were least severe with atezolizumab alone vs sunitinib (IMmotion150; ClinicalTrials.gov Identifier: NCT01984242).

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Pal SK, McDermott DF, Atkins MB, et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020. PMID: 32233107. doi:10.1111/bju.15058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。